Increased private funding could add further to the ethical and legal complexities that are associated with biobanks.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Tensions in ethics and policy created by National Precision Medicine Programs
Human Genomics Open Access 17 April 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Caulfield, T. et al. J. Law Biosci. (in the press).
Critchley, C. R., Nicol, D., Otlowski, M. F. & Stranger, M. J. Eur. J. Public Health 22, 139–144 (2012).
Clemence, M. et al. Wellcome Trust Monitor Wave 2: Tracking Public Views on Science, Biomedical Research and Science Education (Wellcome Trust, 2013).
Caulfield, T., Rachul, C. & Nelson, E. Biopreserv. Biobank. 10, 433–438 (2012).
Master, Z., Nelson, E., Murdoch, B. & Caulfield, T. Nature Methods 9, 885–888 (2012).
Zawati, M. H., Borry, P. & Howard, H. C. Hum. Genet. 130, 425–432 (2011).
Acknowledgements
The authors would like to thank the co-authors of Caulfield et al. J. Law Biosci. (2014) and AllerGen NCE; the Stem Cell Network; and FP7-project EUcelLex and COST-action 1303 for funding support.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Caulfield, T., Borry, P. & Gottweis, H. Industry involvement in publicly funded biobanks. Nat Rev Genet 15, 220 (2014). https://doi.org/10.1038/nrg3704
Published:
Issue date:
DOI: https://doi.org/10.1038/nrg3704
This article is cited by
-
Tensions in ethics and policy created by National Precision Medicine Programs
Human Genomics (2018)